TEMPO

XORTX Announces New Clinical Advisory Board Member

Retrieved on: 
Wednesday, March 27, 2024
Sanofi, Database, Internal medicine, Critical Path Institute, XRX, TEMPO, Patient, Research, Biomarker, TAME, Polycystic kidney disease, National Institutes of Health, MD, Kidney disease, European Medicines Agency, Publication, PKD, Clinical trial, Boston Medical Center, Therapy, Grady Memorial Hospital, FDA, Food, Pharmaceutical industry

CALGARY, Alberta, March 27, 2024 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANUA WKN: A3UNZ), a biopharmaceutical company focused on developing innovative therapies to treat autosomal dominant polycystic kidney disease (“ADPKD”), is pleased to announce that Dr. Ronald Perrone has joined the Company’s Clinical Advisory Board.

Key Points: 
  • CALGARY, Alberta, March 27, 2024 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANUA WKN: A3UNZ), a biopharmaceutical company focused on developing innovative therapies to treat autosomal dominant polycystic kidney disease (“ADPKD”), is pleased to announce that Dr. Ronald Perrone has joined the Company’s Clinical Advisory Board.
  • Dr. Allen Davidoff stated, “We are excited that Dr. Ron Perrone has agreed to join XORTX’s Clinical Advisory Board.
  • Dr. Perrone brings substantial medical and professional experience as a thought leader, combined with clinical experience treating patients with ADPKD and kidney disease.
  • We are privileged to have Dr. Perrone join our esteemed Clinical Advisory Board alongside current members, Dr. Petter Bjornstad, Dr. Richard Johnson, Dr. Federico Maese, Dr. Anjay Rostogi and Dr. Charles Edelstein.

HARMONY BIOSCIENCES INITIATES GLOBAL PHASE 3 REGISTRATIONAL TRIAL (TEMPO STUDY) OF PITOLISANT IN PATIENTS WITH PRADER-WILLI SYNDROME

Retrieved on: 
Wednesday, April 3, 2024
ODD, Narcolepsy, Prader–Willi syndrome, TEMPO, Cataplexy, Patient, Ageing, EDS, Safety, Harmony, Plasma protein binding, FDA, PWS, Pitolisant, Pharmaceutical industry

Approximately 15,000 – 20,000 people in the U.S. are living with PWS, the majority experiencing behavioral symptoms and more than half with EDS.

Key Points: 
  • Approximately 15,000 – 20,000 people in the U.S. are living with PWS, the majority experiencing behavioral symptoms and more than half with EDS.
  • "Our progress in expanding the clinical applications of pitolisant in PWS and in other rare diseases, remains promising.
  • Pitolisant is marketed as WAKIX® in the U.S. and is FDA approved to treat EDS or cataplexy in adult patients with narcolepsy.
  • Pitolisant is not approved for use in patients with PWS and is currently being evaluated as an investigational agent in this patient population.

HARMONY BIOSCIENCES RECEIVES U.S. FOOD AND DRUG ADMINISTRATION ORPHAN DRUG DESIGNATION FOR PITOLISANT IN PRADER-WILLI SYNDROME

Retrieved on: 
Tuesday, February 20, 2024
Caregiver, Orphan drug, Narcolepsy, FDA, Food, TEMPO, Prader–Willi syndrome, Phase 3, Safety, PWS, EDS, Patient, Science, Plasma protein binding, Pharmaceutical industry

PLYMOUTH MEETING, Pa., Feb. 20, 2024 /PRNewswire/ -- Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY), announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug designation to pitolisant for the treatment of Prader-Willi syndrome (PWS).

Key Points: 
  • PLYMOUTH MEETING, Pa., Feb. 20, 2024 /PRNewswire/ -- Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY), announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug designation to pitolisant for the treatment of Prader-Willi syndrome (PWS).
  • "The decision to grant Orphan Drug designation to pitolisant indicates that it could be a promising treatment option for people living with Prader-Willi syndrome," said Kumar Budur, M.D., M.S., Chief Medical Officer at Harmony Biosciences.
  • FDA Orphan Drug designation incentivizes the advancement of promising therapies for rare diseases by providing tax credits for clinical development, waivers for user fees, and seven years of market exclusivity following drug approval.
  • In the upcoming Phase 3 registrational TEMPO study, Harmony will assess the safety and efficacy of pitolisant in treating EDS and behavioral disturbances in PWS.

Parsons Merges Artificial Intelligence To Deliver Combat Advantage

Retrieved on: 
Thursday, December 14, 2023
Software, Parsons Corporation, Environment, CEMA, TEMPO, PSN, Artificial intelligence, Intelligence, Algorithm, Telescopic sight

CHANTILLY, Va., Dec. 14, 2023 (GLOBE NEWSWIRE) -- Parsons Corporation (NYSE: PSN) is using artificial intelligence (AI) to combine combat-tested technologies with historically challenging Cyber and Electromagnetic Activities (CEMA) capabilities to deliver combat advantage to warfighters operating at the tactical edge.

Key Points: 
  • CHANTILLY, Va., Dec. 14, 2023 (GLOBE NEWSWIRE) -- Parsons Corporation (NYSE: PSN) is using artificial intelligence (AI) to combine combat-tested technologies with historically challenging Cyber and Electromagnetic Activities (CEMA) capabilities to deliver combat advantage to warfighters operating at the tactical edge.
  • Parsons developed the software to optimize the combat advantage planning to simulate the CEMA environment and identify optimal sensor placement and configuration.
  • “Our software provides our warfighters with a force-multiplier for planning real-time CEMA missions,” said Joe Zirilli, vice president of artificial intelligence for Parsons.
  • Parsons is leveraging decades of artificial intelligence expertise to deliver tactical solutions at the speed and scale of combat.

Cerevel Therapeutics to Host Investor Webcast on Tavapadon in Parkinson’s Disease

Retrieved on: 
Wednesday, November 29, 2023
Cleveland Clinic, Neurology, Hope, TEMPO, Therapy, L-DOPA, Pharmaceutical industry

CAMBRIDGE, Mass., Nov. 29, 2023 (GLOBE NEWSWIRE) -- Cerevel Therapeutics (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, announced it will host a tavapadon investor webcast on Monday, December 11, from 10:00 to 11:30 a.m. ET.

Key Points: 
  • ET
    CAMBRIDGE, Mass., Nov. 29, 2023 (GLOBE NEWSWIRE) -- Cerevel Therapeutics (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, announced it will host a tavapadon investor webcast on Monday, December 11, from 10:00 to 11:30 a.m.
  • Cerevel will lead an in-depth discussion of tavapadon, its D1/D5 partial agonist currently in Phase 3 development for the treatment of Parkinson’s disease.
  • Tavapadon is currently being studied for Parkinson’s disease in the Phase 3 TEMPO program.
  • Following the live webcast, an archived version of the event will be available on the website.

Tune Therapeutics Presents First Data Supporting TUNE-401: a First-in-Class Epigenetic Silencer for Hepatitis B

Retrieved on: 
Wednesday, December 6, 2023
Research, Infectious Diseases, Genetics, Clinical Trials, Other Health, Biotechnology, General Health, Health, Science, Other Science, DNA methylation, Chromosome, DNA, Therapy, Hepatitis B virus, Liver, Tune, Mouse, HBV, Patient, TEMPO, Chimera, Hepatocyte, PCSK9, Genome, FRG, Vaccine, Dietary supplement, Medical device, CccDNA

Leading epigenome editing company Tune Therapeutics presented data in support of its chronic Hepatitis B Virus (HBV) program, demonstrating the ability to durably silence essential mechanisms of viral replication and persistence across a range of model systems.

Key Points: 
  • Leading epigenome editing company Tune Therapeutics presented data in support of its chronic Hepatitis B Virus (HBV) program, demonstrating the ability to durably silence essential mechanisms of viral replication and persistence across a range of model systems.
  • Importantly, the TEMPO platform does this via epigenetic processes, and without cutting, damaging, or altering genomic DNA sequences in any way.
  • “Through the richness of these data sets, we found multiple repression candidates that worked well in both contexts.
  • As such, they represent the gold standard for assessing the dose and efficacy for liver-directed therapeutics ahead of human clinical trials.

Tune Therapeutics Reveals Epigenetic Editing Program Targeting Hepatitis B Virus

Retrieved on: 
Monday, November 13, 2023
Biotechnology, Infectious Diseases, Health, Genetics, Clinical Trials, Hepatology, DNA, Therapy, Hepatitis B virus, AASLD, Tune, HBV, Multimedia, Patient, TEMPO, CccDNA, Genome, Standard of care, University, Epigenetics, SOC, Vaccine, Medicine, Boston

Pioneering epigenome editing company Tune Therapeutics has announced it is working on a new and potentially curative approach to treating chronic HBV infection.

Key Points: 
  • Pioneering epigenome editing company Tune Therapeutics has announced it is working on a new and potentially curative approach to treating chronic HBV infection.
  • (Graphic: Business Wire)
    The Tune HBV program was unveiled by Dr. Ed Gane, Professor of Medicine at the University of Auckland and world-renowned authority on Hepatitis B Virus (HBV) at the American Association for the Study of Liver Diseases ( AASLD ) conference in Boston, MA on November 11th.
  • As Tune Therapeutics’ Chief Scientific Officer Derek Jantz elucidates, this fact was the crucial driver for a new therapeutic approach using TEMPO.
  • “We can leverage the same, exact mechanism of virus control that we observe in these functionally-cured patients by switching off the virus using a targeted epigenetic silencer.

Annual Science Conference to Feature NASA Leadership, Research

Retrieved on: 
Friday, December 8, 2023
Cloud, Air pollution, Atmosphere of Earth, NASA Earth Science, Troposphere, NASA, Multimedia, TEMPO, Science, Sun, AGU, Earth science, PACE, American Geophysical Union, Communications satellite, Moon, Mars, Artemis

Researchers from across the agency also will present findings throughout the week on Earth sciences, planetary science, and heliophysics beginning on Monday, Dec. 11.

Key Points: 
  • Researchers from across the agency also will present findings throughout the week on Earth sciences, planetary science, and heliophysics beginning on Monday, Dec. 11.
  • New NASA science results from Mars, ice dynamics in Antarctica, and how to determine habitable zones for exoplanets, are among other topics.
  • For those attending the meeting, 50 hyperwall talks at the NASA Exhibit will highlight the current state of NASA Earth, planetary, and heliophysics science.
  • For more information on NASA Earth and climate science, visit:
    View original content to download multimedia: https://www.prnewswire.com/news-releases/annual-science-conference-to-fe...

Deep Decarbonization Scenarios Reveal Importance of Accelerating Zero-Emission Vehicle Adoption

Retrieved on: 
Wednesday, November 1, 2023
Policy, Energy efficiency, Golden, Colorado, U.S. Department of Energy, Office of Inspector General, Behavior, NREL, Federal Department of Environment, Transport, Energy and Communications, Biofuel, Transport, Electricity, TEMPO, Research, Hydrogen, Growth, Nature Communications, Travel, DOE, U.S. Department of Defense Strategy for Operating in Cyberspace, CO, Burn, ZEV, Greenhouse, ZEVS, Sustainable energy, Renewable energy, Energy

“In the scientific community, there is a lot of agreement around what needs to happen to slash transportation-related greenhouse gas emissions, especially when it comes to electrification.

Key Points: 
  • “In the scientific community, there is a lot of agreement around what needs to happen to slash transportation-related greenhouse gas emissions, especially when it comes to electrification.
  • Hoehne’s co-authors from NREL are Matteo Muratori, Paige Jadun, Brian Bush, Artur Yip, Catherine Ledna, and Laura Vimmerstedt.
  • While most vehicles today burn fossil fuels, a zero-emission vehicle (ZEV) relies on alternate sources of power, such as batteries or hydrogen.
  • NREL is the U.S. Department of Energy's primary national laboratory for renewable energy and energy efficiency research and development.

NASA’s Psyche—Maxar Space’s First Deep Space Spacecraft— Performing Well After Launch

Retrieved on: 
Saturday, October 14, 2023
Other Defense, Contracts, Hardware, White House, Federal Government, Technology, Defense, Photography, Aerospace, Congressional News, Views, Manufacturing, Telecommunications, Public Policy, Government, TEMPO, Multimedia, Field line, Power and Propulsion Element, Artemis program, Maxar Technologies, Travel, Power, SEP, Tropospheric Emissions: Monitoring of Pollution, Noetics, Arizona State University, Troposphere, Spacecraft, NASA, Communications satellite, Transport, Psyche, California Institute of Technology, Xenon

Maxar Space, provider of comprehensive space solutions and secure, precise, geospatial intelligence, built the unique spacecraft chassis based on the Maxar 1300™ series bus, the world’s most trusted space platform.

Key Points: 
  • Maxar Space, provider of comprehensive space solutions and secure, precise, geospatial intelligence, built the unique spacecraft chassis based on the Maxar 1300™ series bus, the world’s most trusted space platform.
  • The Maxar Space-built Psyche chassis spread its two solar arrays and successfully started maneuvers toward the asteroid belt.
  • (Photo: Maxar Space)
    This Maxar 1300 spacecraft is one of the lightest and smallest ever, showing the versatility of the platform.
  • “Psyche will break records for deep space travel using SEP,” said Chris Johnson, CEO for Maxar Space.